experimental therapy

The country’s provisional go-ahead could increase pressure already being exerted on the US Food and Drug Administration to approve the therapy.

Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.

There is little evidence that antihypertensive drugs worsen COVID-19, and scientists are instead exploring the idea that such medications—or their downstream effects—may actually alleviate symptoms.

The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?

REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.

The announcement comes as the country prepares for possible spread of the virus from Democratic Republic of Congo.

The agency cites safety concerns with customers of Genetech who reported getting E. coli infections and sends letters to other stem cell companies reminding them to follow the rules.

The FTC, in its first crack down on the industry, gets two California companies selling unproven treatments to stop their false advertising and pay a fine.

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

The World Health Organization predicts the number of cases in Democratic Republic of Congo will rise up to 300 by July.  

A total of 27 people have died since April, but new funds and the deployment of an experimental vaccine are expected to help contain the virus.

The stunt, performed at a biohacking conference, was purportedly part of a two-subject trial of the genetically modified vaccine.

A $42 million US government contract awarded to an experimental Ebola medicine maker aims to accelerate the process of meeting demand for the therapeutic.

ZMapp effectively rescued macaques from Ebola in a small trial, but it could be several months before supplies of the drug meet the growing human demand for it.

But biotech firms’ supplies are dwindling.

As the World Health Organization calls the ongoing Ebola outbreak in West Africa an international public health emergency, the US Food and Drug Administration green-lights the potential use of another experimental drug.

The administration of an experimental serum to two American healthcare workers treated for Ebola on US soil raises questions of safety, efficacy, access, and ethics.

An experimental monoclonal antibody therapy, tested only in animals, is given to two Americans infected with Ebola virus.